IDA Business Park Bray,
County Wicklow,
A98 H5C8 Ireland
VIA EDGAR
June 4, 2026
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E. Washington, D.C. 20549
Request for Withdrawal of Amendment on Form F-1/A
File No. 333-293717
Dear Ms. Dickerson:
Pursuant to Rule 477 under the Securities Act of 1933, as amended, Trinity Biotech plc (the “Company”) hereby respectfully requests that the Securities and Exchange Commission (the “Commission”) consent to the withdrawal, effective as of the date hereof or as soon as practicable hereafter, of the Company’s amendment on Form F-1/A, together with all exhibits thereto, filed with the Commission on June 3, 2026 (the “Amendment”) to the Company’s Registration Statement on Form F-1 (File No. 333-293717), originally declared effective on March 3, 2026.
The Company is requesting withdrawal of the Amendment because it was inadvertently submitted under the EDGAR submission type “F-1/A,” which is used for a pre-effective amendment, rather than “POS AM,” which is used for a post-effective amendment. The Company intends to promptly re-file the Amendment under the correct EDGAR submission type “POS AM,” with no substantive changes other than the submission type.
The Amendment has not been declared effective by the Commission, and no securities have been issued or sold under the Amendment.
If you have any questions or comments regarding this request, please contact Mary Brown of Carter Ledyard & Milburn LLP at (212) 238-8765.
By: _/s/ John Gillard___________________
Name: John Gillard
Title: Chief Executive Officer